Clinical trial
Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection
NCT00133172 · Astellas Pharma Inc, Industry · Terminated
Key facts
| NCT number | NCT00133172 |
|---|---|
| Title | Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection |
| Official title | Evaluation of the Long-term Safety and Efficacy of a Tacrolimus-based 5-day Steroid Rapid Withdrawal Immunoprophylactic Regimen in de Novo Renal Transplantation |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma Canada, Inc. Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Kidney Transplantation |
| Intervention type | Drug |
| Interventions | Tacrolimus, mycophenolate mofetil, Prednisone |
| Enrollment | 85 |
| Start date | Jul 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Aug 23, 2005 |
| Last update posted | Sep 8, 2014 |
| Countries | Canada |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: